Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
John G. Stratton, a director of Abbott Laboratories (ABT), had 293 stock-equivalent units credited on 09/30/2025 under a grantor trust that converts director fees into units that track Abbott share returns. The units are valued at $133.94 each in this filing and the reporting person’s total beneficial ownership after the transaction is reported as 12,663 shares or share equivalents. The filing explains these units are paid in cash generally at age 65 or upon retirement from the board and that the balance includes units from a dividend reinvestment feature. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Patricia Paola Gonzalez, a director of Abbott Laboratories (ABT), had a non-derivative transaction on 09/30/2025 that credited 246 stock equivalent units at an indicated per-share reference of $133.94. After the reported transaction, the filing shows she beneficially owned 4,922 shares/stock-equivalent units. The filing explains these credits represent director fees placed into a stock equivalent unit account under a director grantor trust, which are paid in cash generally at age 65 or upon retirement from the board and earn the same return as if invested in Abbott shares. The reported Form 4 was signed via attorney-in-fact on 10/02/2025.
Robert J. Alpern, a director of Abbott Laboratories (ABT), reported a transaction dated 09/30/2025 on a Form 4. The filing shows an acquisition of 58 common share equivalents recorded at $133.94 per share and a post-transaction beneficial balance of 10,300 stock-equivalent units. The filing notes these units represent director fees credited to a grantor trust that mirror Abbott share returns and are generally paid in cash at age 65 or upon board retirement; the balance also includes units from a dividend reinvestment feature. The Form 4 was signed on behalf of Mr. Alpern by an attorney-in-fact on 10/02/2025.
Abbott Laboratories reporting person John A. McCoy Jr., Vice President and Controller, is disclosed as selling 79 common shares on 09/01/2025 at a price of $132.66 per share. After the reported disposition, Mr. McCoy beneficially owns 20,982 common shares directly. The filing also notes an indirect interest in Abbott shares held in a profit sharing/stock retirement trust, with the balance in that trust stated as of September 1, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. McCoy on 09/03/2025.
Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares. He also reports indirect beneficial ownership of 363 shares held in a Profit Sharing Trust. The filing is signed by an attorney-in-fact on behalf of Mr. Boudreau.
Philip P. Boudreau, EVP and CFO of Abbott Laboratories (ABT), filed a Form 4 reporting insider sales dated 08/08/2025. The filing lists a sale transaction reported at a weighted average price of $134.551 and notes transaction prices in the range $134.551 to $134.58. The table shows 5,550 shares sold (denoted D) and a direct beneficial ownership following the reported transaction of 51,003 shares. It also reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.
The Form 4 is signed on behalf of Mr. Boudreau by an attorney-in-fact and dated 08/11/2025. The filing includes an explicit offer to provide detailed per-price sale breakdowns upon request and discloses the reporting person’s title and relationship to the issuer. No additional financial metrics, forward-looking statements, or explanations of purpose for the sale are provided in the filing.
Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.
The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.